Knight Therapeutics Inc T.GUD

Repurchases so far from NCIB

[GoldenInvestor]

- has there been more than the 450k, as recently discussed?

- with total NCIB potential , when management sees favourable, they could originally  Re-purchase up to almost 8,000,000 shares.

- so with approximately the 7,500,000 possible share redemption remaining, and operations continuing to evolve at a less restrictive, or adaptive post-covid pace, profits from increasing sales will be going to significantly less shares.

[EbbFlow88]

Of the 8M shares that we can purchase, we've purchased a little over 2.5M from my calculations. It's a slower pace than last year but we're on pace for ~5M shares, which would bring us to around 110M shares. Totally agree on your last statement and that's why share buybacks are so powerful with rising earnings / cash flow. 

[GoldenInvestor]

Thanks for the correction on amount so far.  Good to see they still could continue to reduce shares outstanding. Another 5.5 million.

[Chianchin]

For anyone reading this forum, these three Jokers Aliases is one person provide a sht show illusion 

[Eoj123]

I'm sure glad I sold this about a half a dozen years ago shorly after they sold their priority review voucher and just after their run to $10. It's been a dog since

[MrMugsy]

Well done EOJ. You don't hold these shares unless you're doing it the way you did it with Paladin. Only a handful of investors here - accumulating for the long-term. What did I say ... ~60 investors (give or take) holding 70% of the company. Tough to say how many own the remaining 30% - but let's call about half of them transient. And ... the biggest moves that really rock the

[Snowballgrowth]

Not much new info since last Q results. What do you watch until next Q ? Do we have clues about Exelon sales once they did the transition with Novartis ? GUD expertise is to market unpromoted products. Should ne interesting to see if they get sales growth with the larger pipeline

[MrMugsy]

Novarits/Exelon is interesting ... wondering if it could lead to additional drug partnerships with Novartis in the future - if GUD can do better in those regions than Novartis can.  Would GUD make a good partner with Novartis in ROW?  Tough to say, just watching to see what might happen next. Does Exelon have additional indications for the future?  Waiting to see where they take

[Snowballgrowth]

Yeah some potential update there but short term I don't see any significant catalyst. I guess we will have to wait next Q results to get more info. Growth and EBITDA are keys here. 

[Chianchin]

Obsession and psychosis are logterm conditions, Mr Mugsy + Aliases who mugsy beleives are real persons and write to eachothers  have kept rubbing the Paladin lamp for 10 Years.  No Jeene out yet or ever